Anixa Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Anixa Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-4.5%

Buyback Yield

Total Shareholder Yield	-4.5%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

Recent updates

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ANIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIX's dividend payments have been increasing.

Dividend Yield vs Market

Anixa Biosciences Dividend Yield vs Market

How does ANIX dividend yield compare to the market?
Segment	Dividend Yield
Company (ANIX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.5%
Industry Average (Biotechs)	2.4%
Analyst forecast (ANIX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate ANIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ANIX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIX has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 09:15
End of Day Share Price	2024/12/24 00:00
Earnings	2024/07/31
Annual Earnings	2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anixa Biosciences, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew D'Silva	B. Riley Securities, Inc.
Jason Kolbert	D. Boral Capital LLC.
Yi Chen	H.C. Wainwright & Co.

Anixa Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Recent updates

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting

Now 20% undervalued

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial

New minor risk - Share price stability

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Lead Independent Director recently bought US$84k worth of stock

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

CEO, Chairman & Co-Chair of CBAB recently bought US$60k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board

CEO, Chairman & Co-Chair of CBAB recently bought US$97k worth of stock

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024

New minor risk - Share price stability

Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board

Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board

Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Lead Independent Director exercised options to buy US$119k worth of stock.

Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Now 38% undervalued after recent price drop

Price target increased by 11% to US$10.50

Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

Insufficient new directors

Insufficient new directors

Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic

Lead Independent Director exercised options to buy US$197k worth of stock.

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Chairman & CEO exercised options and sold US$937k worth of stock

Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Anixa to get additional US patent linked to breast cancer vaccine technology

Lead Independent Director exercised options to buy US$144k worth of stock.

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Price target increased to US$11.00

Anixa Biosciences, Inc. Announces Management Changes

Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Chairman recently bought US$60k worth of stock

Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant

Lead Independent Director recently bought US$87k worth of stock

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant

Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

Board Member recently bought US$82k worth of stock

Lead Independent Director recently bought US$87k worth of stock

Consensus forecasts updated

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation